KR102127826B1 - 암 치료용 수액제 조성물 - Google Patents
암 치료용 수액제 조성물 Download PDFInfo
- Publication number
- KR102127826B1 KR102127826B1 KR1020180110318A KR20180110318A KR102127826B1 KR 102127826 B1 KR102127826 B1 KR 102127826B1 KR 1020180110318 A KR1020180110318 A KR 1020180110318A KR 20180110318 A KR20180110318 A KR 20180110318A KR 102127826 B1 KR102127826 B1 KR 102127826B1
- Authority
- KR
- South Korea
- Prior art keywords
- sugar
- solution
- cells
- infusion
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
도 2a는 본 발명의 조성물에 대한 세포 침윤성 억제 실험에서 전이된 세포를 촬영한 것이고, 도 2b는 침윤성 억제를 비교한 그래프이다.
도 3a 및 도 3b는 본 발명의 조성물에 대한 세포 이동성 억제 실험에서 웰 플레이트를 촬영한 사진이고, 도 3c 및 도 3d는 이동성 억제를 비교한 그래프이다.
| 성분 |
당 함유
수액제 |
|
| 당 (mg) | L-(-)-Fucose | 31 |
| D-(+)-Galactose | 31 | |
| D-(+)-Xylose | 31 | |
| D-(+)-Glucose | 31 | |
| D-(+)-Mannose | 31 | |
| N-Acetylneuraminic acid | 31 | |
| N-Acetyl-D-galactosamine | 31 | |
| N-Acetyl-D-glucosamine | 31 | |
| 안정화제 (mg) | Aspartic acid | 20 |
| 용제 | 주사용수 | q.s. |
| pH 조절제 (μL) |
1N NaOH | q.s. |
| Total | 10 mL |
| 성분 |
당 및 아미노산
함유 수액제 |
|
| 당 (mg) | L-(-)-Fucose | 31 |
| D-(+)-Galactose | 31 | |
| D-(+)-Xylose | 31 | |
| D-(+)-Glucose | 31 | |
| D-(+)-Mannose | 31 | |
| N-Acetylneuraminic acid | 31 | |
| N-Acetyl-D-galactosamine | 31 | |
| N-Acetyl-D-glucosamine | 31 | |
| 아미노산 (mg) | L-Isoleucine | 28 |
| L-Leucine | 62.5 | |
| L-Lysine Acetate | 62 | |
| L-Methionine | 17.5 | |
| L-Phenylalanine | 46.75 | |
| L-Threonine | 32.5 | |
| L-Tryptophan | 6.5 | |
| L-Valine | 22.5 | |
| L-Alanine | 31.25 | |
| L-Arginine | 39.5 | |
| L-Aspartic Acid | 19 | |
| L-Cysteine | 5 | |
| L-Glutamic Acid | 32.5 | |
| L-Histidine | 30 | |
| L-Proline | 16.5 | |
| L-Serine | 11 | |
| L-Tyrosine | 1.75 | |
| Aminoacetic Acid | 53.5 | |
| 안정화제 (mg) | Aminoguanidine | 40 |
| 용제 | 주사용수 | q.s. |
| pH 조절제 (μL) |
1N NaOH | q.s. |
| Total | 10 mL |
Claims (4)
- 삭제
- 글루코스, 갈락토스, 만노스, 푸코스, 자일로스, N-아세틸글루코사민, N-아세틸갈락토사민 및 N-아세틸뉴라민산을 포함하며, 추가로 아미노산을 더 포함하는 암 치료용의 정맥 주사용 수액제 조성물.
- 제2항에 있어서, 상기 아미노산은 이소류신, 류신, 리신아세테이트, 메티오닌, 페닐알라닌, 트레오닌, 트립토판, 발린, 알라닌, 아르기닌, 아스파라긴산, 시스테인, 글루타민산, 히스티딘, 프롤린, 세린, 티로신, 및 글리신으로 이루어진 군으로부터 1종 이상 선택되는 것을 특징으로 하는 수액제 조성물.
- 제2항에 있어서, 상기 아미노산은 단백질을 구성할 수 있는 20종의 아미노산 중 1종 이상인 것을 특징으로 하는 수액제 조성물.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180110318A KR102127826B1 (ko) | 2018-09-14 | 2018-09-14 | 암 치료용 수액제 조성물 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180110318A KR102127826B1 (ko) | 2018-09-14 | 2018-09-14 | 암 치료용 수액제 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200031735A KR20200031735A (ko) | 2020-03-25 |
| KR102127826B1 true KR102127826B1 (ko) | 2020-06-29 |
Family
ID=70001847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180110318A Active KR102127826B1 (ko) | 2018-09-14 | 2018-09-14 | 암 치료용 수액제 조성물 |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102127826B1 (ko) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812222B1 (en) | 1995-08-11 | 2004-11-02 | George Wu | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
| KR100594353B1 (ko) | 2002-05-28 | 2006-07-03 | 주식회사 엠디바이오알파 | 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6178719A (ja) * | 1984-09-25 | 1986-04-22 | Tanabe Seiyaku Co Ltd | 総合輸液剤 |
| KR100450097B1 (ko) * | 1996-08-09 | 2004-09-30 | 마나테크 인코포레이티드 | 식이 보조제 용도의 식물 탄수화물 조성물 |
| KR20110131699A (ko) | 2010-05-31 | 2011-12-07 | 한올바이오파마주식회사 | 영양공급에 따른 부작용의 예방 또는 치료를 위한 정맥주사 수액제 |
| KR20180110318A (ko) * | 2017-03-28 | 2018-10-10 | 삼성디스플레이 주식회사 | 표시 기판 |
-
2018
- 2018-09-14 KR KR1020180110318A patent/KR102127826B1/ko active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812222B1 (en) | 1995-08-11 | 2004-11-02 | George Wu | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
| KR100594353B1 (ko) | 2002-05-28 | 2006-07-03 | 주식회사 엠디바이오알파 | 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물 |
Non-Patent Citations (2)
| Title |
|---|
| 1020180110318_0001 |
| 1020180110318_0002 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200031735A (ko) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2823279T3 (es) | Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab | |
| Wolf et al. | Isolation, physicochemical properties, and the macromolecular composition of the vitelline and fertilization envelopes from Xenopus laevis eggs | |
| Brady et al. | Composition and synthesis of gangliosides in rat hepatocyte and hepatoma cell lines | |
| Nishihara et al. | Isolation and characterization of a lectin from the cortical granules of Xenopus laevis eggs | |
| Starnes et al. | Human liver aminopeptidase. Amino acid and carbohydrate content, and some physical properties of a sialic acid-containing glycoprotein | |
| CN1313493C (zh) | 包括加热处理步骤的人血清白蛋白的制造方法 | |
| Lampen | 10 Yeast and Neurospora Invertases | |
| Kakazu et al. | Plasma amino acids imbalance in cirrhotic patients disturbs the tricarboxylic acid cycle of dendritic cell | |
| JP2018109064A (ja) | ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物 | |
| KR102127826B1 (ko) | 암 치료용 수액제 조성물 | |
| Michuda et al. | Mitochondrial aspartate transaminase. II. Isolation and characterization of the multiple forms | |
| Kost et al. | New feature of angiotensin‐converting enzyme: carbohydrate‐recognizing domain | |
| Yang et al. | Structures and biosynthesis of the N-and O-glycans of recombinant human oviduct-specific glycoprotein expressed in human embryonic kidney cells | |
| EP3597177B1 (en) | Glucose infusion solution composition | |
| JP2024527517A (ja) | 抗ｐｄ１抗体製剤 | |
| Krause et al. | N-Terminal pyrazinones: a new class of peptide-bound advanced glycation end-products | |
| Kruse Jr et al. | Amino acid utilizations and protein synthesis at various proliferation rates, population densities, and protein contents of perfused animal cell and tissue cultures | |
| KR102129366B1 (ko) | 염증 치료용 수액제 조성물 | |
| Gensberger et al. | Qualitative profiling of polyglucose degradation products in peritoneal dialysis fluids | |
| CN100516208C (zh) | 卵磷脂化超氧化物歧化酶组合物及其制备方法 | |
| Lu et al. | Conformational study reveals amino acid residues essential for hemagglutinating and anti-proliferative activities of Clematis montana lectin | |
| Kim et al. | Structural identification and quantification of unreported sialylated N-glycans in bovine testicular hyaluronidase by LC-ESI-HCD-MS/MS | |
| US20220204654A1 (en) | Cyclodextrin supramolecular scaffolds and uses thereof | |
| CN119776469A (zh) | 一种高半乳糖含量酸性海参糖蛋白及其在降低餐后血糖中的应用 | |
| KR20230085400A (ko) | 항바이러스용 수액제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20180914 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190104 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20180914 Comment text: Patent Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20190104 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20180914 Patent event code: PA03021R01I Comment text: Patent Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190508 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20200107 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20190508 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20200107 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20191108 Comment text: Amendment to Specification, etc. |
|
| PX0701 | Decision of registration after re-examination |
Patent event date: 20200324 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20200313 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20200107 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20191108 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
| X701 | Decision to grant (after re-examination) | ||
| PG1501 | Laying open of application | ||
| PN2301 | Change of applicant |
Patent event date: 20200619 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200623 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200623 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20230325 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240408 Start annual number: 5 End annual number: 5 |